Cell Cycle/Checkpoint
Cell cycle/checkpoint inhibitors are compounds that disrupt the normal progression of the cell cycle, particularly at key regulatory checkpoints. These inhibitors are crucial for studying cell division, understanding cancer cell proliferation, and developing anti-cancer therapies. By targeting specific phases of the cell cycle, these inhibitors can induce cell cycle arrest, leading to apoptosis or senescence in rapidly dividing cells. At CymitQuimica, we offer a diverse range of high-quality cell cycle/checkpoint inhibitors to support your research in cancer biology, cell biology, and drug development.
Subcategories of "Cell Cycle/Checkpoint"
- Aurora Kinase(112 products)
- CDK(540 products)
- Cell Cycle Arrest(5 products)
- Chk(46 products)
- DYRK(48 products)
- Dynamin(27 products)
- Ferroptosis(227 products)
- HSP(181 products)
- Integrin(265 products)
- Kinesin(88 products)
- LIM Kinase(20 products)
- Microtubule Associated(280 products)
- PKC(117 products)
- PLK(25 products)
- ROCK(63 products)
- Rho(5 products)
- Wee1(14 products)
- c-Myc(77 products)
Show 10 more subcategories
Found 3855 products of "Cell Cycle/Checkpoint"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
DYRK1-IN-1
CAS:DYRK1-IN-1: Selective DYRK1A inhibitor with IC50 of 220 nM, good permeability, CNS penetrant for research, no P-glycoprotein issues.Formula:C12H12N6Color and Shape:SolidMolecular weight:240.26Plevitrexed
CAS:Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.Formula:C26H25FN8O4Purity:98%Color and Shape:SolidMolecular weight:532.53Werner syndrome RecQ helicase-IN-2
CAS:Werner syndrome RecQ helicase-IN-2 is a potent Werner syndrome RecQ DNA helicase (WRN) inhibitor, useful in research on colorectal and gastric cancers.Formula:C32H34F3N9O5Purity:99.02%Color and Shape:SolidMolecular weight:681.67PD-L1-IN-7
CAS:PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.Formula:C46H50N6O7Color and Shape:SolidMolecular weight:798.93RAD51-IN-8
RAD51-IN-8 inhibits RAD51-BRCA2 interaction and H4A4 with EC50 of 19 μM; a micromolar PPI inhibitor.Formula:C16H14Cl2FN3O2Color and Shape:SolidMolecular weight:370.21PolQi1
CAS:PolQi1 is a highly efficient and selective Polϴ (DNA polymerase theta) inhibitor with an IC50 of 2 nM, showing potential for cancer therapy.Formula:C18H14ClF5N4O2Purity:98.97%Color and Shape:SolidMolecular weight:448.77Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40CDK4/6-IN-13
CAS:Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.Formula:C25H29N7OColor and Shape:SolidMolecular weight:443.54Dyrk1A/α-synuclein-IN-1
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM).Formula:C20H21N5O3SColor and Shape:SolidMolecular weight:411.48GTSE1-IN-1
CAS:GTSE1-IN-1 (compound Y18), an orally active GTSE1 inhibitor, exhibits notable anticancer properties. It effectively represses the proliferation of cancer cells by downregulating GTSE1 transcription and expression, which leads to DNA damage and promotes persistent cell cycle arrest and cellular senescence. Moreover, GTSE1-IN-1 substantially reduces the adhesion, migration, and invasion of colorectal cancer HCT116 cells and non-small cell lung cancer A549 cells in vitro.Formula:C21H24FN7Color and Shape:SolidMolecular weight:393.466-N-Hydroxylaminopurine
CAS:6-N-Hydroxylaminopurine is a base analog with mutagenic activity.Formula:C5H5N5OMolecular weight:151.132′-OMe-ADP
CAS:2′-OMe-ADP is a nucleotide analogue used in oligonucleotide synthesis.Formula:C11H17N5O10P2Color and Shape:SolidMolecular weight:441.23Des-ethyl-carafiban
CAS:Des-ethyl-carafiban (Compound 44) is an antagonist of the fibrinogen receptor, effectively inhibiting platelet aggregation induced by various agonists. It is useful for research in thrombotic diseases.Formula:C22H23N5O5Color and Shape:SolidMolecular weight:437.448Adafosbuvir
CAS:Adafosbuvir has antiviral activity.Formula:C22H29FN3O10PColor and Shape:SolidMolecular weight:545.457CDK8-IN-5
CAS:CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.Formula:C26H22N2O4Color and Shape:SolidMolecular weight:426.468-Azakinetin riboside
CAS:8-Azakinetin riboside, a structural analog of kinetin riboside, exhibits cytotoxic activity [1].Formula:C14H16N6O5Color and Shape:SolidMolecular weight:348.31PROTAC CDK12/13 Degrader-1
PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.Color and Shape:SolidRNase L ligand 3
CAS:RNase L ligand 3 is an RNase L ligand employed in the synthesis of F3-PEG8-RiboTAC.Formula:C27H27N3OSColor and Shape:SolidMolecular weight:441.59CDK9/PARP-IN-1
CAS:CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Formula:C38H34F2N8O3Color and Shape:SolidMolecular weight:688.725isoGTP lithium
CAS:isoGTP (Isoguanosine-5'-triphosphate) lithium is a GTP analog.Formula:C10H12Li4N5O14P3Color and Shape:SolidMolecular weight:546.91
